MedTrace Logo

Stigma and Efficacy of Zhizhu Kuanzhong Capsules

NCT05107999 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2022-08-10

No results posted yet for this study

Summary

Antidepressants are effective in patients with functional dyspepsia (FD), however, the stigma related with FD and antidepressants could affect treatment adherence and efficacy. Zhi Zhu Kuan Zhong capsules (ZZKZ), a traditional Chinese medicine fomula, showed therapeutic potential for FD. The study was designed to investigate whether ZZKZ could alleviate stigma in FD and obtain identical effects in patients with refractory FD.

Conditions

  • Functional Gastrointestinal Disorders
  • Dyspepsia
  • Psychosomatic Disorder

Interventions

DRUG

Zhizhu Kuanzhong capsules (ZZKZ)

FD patients were treated with ZZKZ and omeprazole for 4 weeks.

DRUG

Doxepin Hydrochloride (Doxepin)

FD patients were treated with doxepin and omeprazole for 4 weeks.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Sheng-Liang Chen, PhD · Division of Gastroenterology and Hepatology, Renji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-08-01
Completion
2022-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05107999 on ClinicalTrials.gov